MedTrace Logo

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

NCT01902173 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2025-01-14

Study results available
· View outcomes & findings →

Summary

This phase I/II trial studies the side effects and the best dose of uprosertib when given together with dabrafenib and trametinib and to see how well they work in treating patients with stage IIIC-IV cancer. Uprosertib, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving uprosertib with dabrafenib and trametinib may be a better treatment for cancer.

Conditions

  • Hematopoietic and Lymphoid Cell Neoplasm
  • Locally Advanced Malignant Solid Neoplasm
  • Locally Advanced Melanoma
  • Metastatic Malignant Solid Neoplasm
  • Metastatic Melanoma
  • Stage IIIC Cutaneous Melanoma AJCC v7
  • Stage IV Cutaneous Melanoma AJCC v6 and v7
  • Unresectable Malignant Solid Neoplasm
  • Unresectable Melanoma

Interventions

PROCEDURE

Biopsy

Undergo a biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo a CT scan

DRUG

Dabrafenib Mesylate

Given PO

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

DRUG

Trametinib Dimethyl Sulfoxide

Given PO

DRUG

Uprosertib

Given PO

Sponsors & Collaborators

Principal Investigators

  • Antoni Ribas · SWOG Cancer Research Network

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-08
Primary Completion
2018-05-16
Completion
2023-12-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01902173 on ClinicalTrials.gov